Research programme: chimeric antigen receptor tumour cell therapy - NantKwest/Sorrento Therapeutics

Drug Profile

Research programme: chimeric antigen receptor tumour cell therapy - NantKwest/Sorrento Therapeutics

Alternative Names: CAR-TNK™; CD123-CAR.TNK™; CD123.TNK™; Chimeric antigen receptor tumor - attacking Neukoplast®; PD-L1-CAR.TNK™; PD-L1.TNK™; PSMA-CAR.TNK™; PSMA.TNK™; ROR1-CAR.TNK™; ROR1.TNK™

Latest Information Update: 19 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Conkwest; Sorrento Therapeutics
  • Developer NantKwest; Sorrento Therapeutics
  • Class Cell therapies
  • Mechanism of Action Immunomodulators; Natural killer cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours
  • Research Prostate cancer

Most Recent Events

  • 26 Aug 2015 Early research in Prostate cancer (Late-stage disease) in USA (unspecified route)
  • 26 Aug 2015 NantKwest plans a phase I trial for Prostate cancer
  • 30 Jun 2015 Preclinical trials in Haematological malignancies in USA (Parenteral) (Sorrento's pipeline, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top